Clinical Payment Process used in Vaccine Trial

Bavarian Nordic, a vaccine-focused biotechnology company based in Denmark, is using Greenphire’s ClinCard Technology Platform in a large, Phase III vaccine trial. The trial will take approximately 1 year and involve 35 investigative sites and more than 4,000 subjects.

 “Bavarian Nordic is looking forward to collaborating with Greenphire to ensure that payments to the 4,000 subjects involved in this trial will impose a minimal burden on the 35 participating investigative sites and will be easy for subjects to use, helping sites to increase subject retention and compliance,” said Siegfried Rösch, Director of Clinical Operations at Bavarian Nordic.

“We are delighted to be working with Bavarian Nordic and to be implementing our ClinCard technology platform that will ensure all subjects involved in this trial receive payments and reimbursements quickly and with reduced cost, risk, and administrative processes,” said Sam Whitaker, CEO and Co-Founder of Greenphire. “Bavarian Nordic’s decision to use the ClinCard system is an example of how Greenphire’s vision for clinical trial payments is increasingly accepted within the global clinical trials industry.”